Frankfurt - Delayed Quote EUR

BridgeBio Pharma, Inc. (2CL.F)

33.94

-0.24

(-0.70%)

At close: May 2 at 3:50:08 PM GMT+2

High Growth Tech Stocks In The US Market May 2025

Over the last 7 days, the United States market has risen by 2.7%, contributing to a 9.6% increase over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive market trends.

Simply Wall St. yesterday

BBIO

VNET

KC
BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations

BridgeBio Pharma ( NASDAQ:BBIO ) First Quarter 2025 Results Key Financial Results Revenue: US$116.6m (down 45% from 1Q...

Simply Wall St. yesterday

BBIO
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday

We recently published an article titled Excellent Earnings Propelled Prices of These 10 Firms. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other stocks that soared on Wednesday. The stock market finished Wednesday’s trading on a lackluster note, with the three major indices finishing mixed, as […]

Insider Monkey 2 days ago

BBIO

^GSPC
BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations

BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales expectations.

Investor's Business Daily 2 days ago

PFE

BBIO

ALNY
Q1 2025 BridgeBio Pharma Inc Earnings Call

Q1 2025 BridgeBio Pharma Inc Earnings Call

Thomson Reuters StreetEvents 2 days ago

BBIO
BridgeBio sales of new heart drug outstrip expectations

In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s market-leading drug.

BioPharma Dive 2 days ago

BBIO

PFE
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

BridgeBio Pharma Inc (BBIO) reports robust financial performance and strategic advancements, driven by the successful launch of Attruby and a strong cash position.

GuruFocus.com 2 days ago

BBIO
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 12% and 86.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 days ago

BBIO
BridgeBio Pharma: Q1 Earnings Snapshot

PALO ALTO, Calif. AP) — BridgeBio Pharma Inc. BBIO) on Tuesday reported a loss of $167.4 million in its first quarter.

Associated Press Finance 3 days ago

BBIO

PANW
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for hypochondroplasia Phase 2 trial fully enrolled significantly ahead of schedule. The first participant was also dosed in the Phase 2 interventional study - Proof-of-principle study of encaleret, an oral calcium-sensing receptor antagonist, in hypoparathyroidism resulted in 78% of N=9 study partici

GlobeNewswire 3 days ago

BBIO
BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential. Ole Andreas Halvorsen is one of the prominent names among former […]

Insider Monkey 3 days ago

BBIO
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM

The authorisation was supported by outcomes from the ATTRibute-CM Phase III trial.

Pharmaceutical Technology 3 days ago

BBIO
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date - In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo- A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30- A 50% reduction in the cumulative frequency of CVH events re

GlobeNewswire 4 days ago

BBIO
Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 9 days ago

BHC

BBIO
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio’s p

GlobeNewswire 10 days ago

BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on April 9, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 20 new employees in restricted stock units for an aggregate of 77,652 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock

GlobeNewswire 21 days ago

BBIO
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysisThis profound treatment effect, due to the near-complete stabilization (≥90%) and binding of TTR, represents the greatest observed benefit to date for ATTRv-CM patients, an ATTR-CM population with poor prognosis In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3

GlobeNewswire last month

BBIO
Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care […]

Insider Monkey last month

BBIO
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relat

GlobeNewswire last month

BBIO
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place i

GlobeNewswire last month

BBIO

Performance Overview

Return	2CL.F	S&P 500 (^GSPC)
YTD	+29.30%	-3.31%
1-Year	+36.63%	+12.29%
3-Year	+356.06%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BridgeBio Pharma, Inc. (2CL.F)

High Growth Tech Stocks In The US Market May 2025

BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations

Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday

BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations

Q1 2025 BridgeBio Pharma Inc Earnings Call

BridgeBio sales of new heart drug outstrip expectations

BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

BridgeBio Pharma: Q1 Earnings Snapshot

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Performance Overview